Synthetic Cannabinoid Analogs

About 180 Life Sciences

180 Life Sciences is a NASDAQ-listed biotech (ATNF) with a mission to address high-unmet-need conditions like Dupuytren's disease and frozen shoulder through targeted anti-TNF therapies and novel cannabinoid science. Its strategy is bifurcated, combining a virtual drug development model with an institutional fintech platform, 'Forum,' for securitizing real-world assets. While its lead program is in Phase 2b, the company operates with a lean structure, relying on academic collaborations and CROs, and faces significant challenges in capital allocation and clinical execution amidst a complex dual-focus business model.

Therapeutic Areas